Preoperative and postoperative correlation of histopathological findings in cases of endometrial hyperplasia

Objectives: To determine the preoperative and postoperative correlation of histopathological findings in cases of endometrial hyperplasia.

Material and methods: One hundred and three patients with endometrial hyperplasia detected by surgical curettage performed due to various gynecologic pathologies were treated by hysterectomy. We compared retrospectively the histopathological diagnoses found on curettage with those found on hysterectomy specimens. The classification scheme endorsed by the International Society of Gynecological Pathologists was used to classify the endometrial hyperplasia. The histologic findings found on the endometrial tissue of curettage specimens were correlated with those from hysterectomy specimens. Histopathologic evaluation was performed by a single skilled gynecologic pathologist.

Results: A total number of 103 women--76 (73.8%) premenopausal and 27 (26.2%) postmenopausal--were determined to have endometrial hyperplasia on histopathological evaluation of endometrial tissues obtained by endometrial curettage performed for evaluation of various bleeding abnormalities. These included 94 patients with simple hyperplasia without atypia (91.3%), two patients with simple hyperplasia with atypia (1.9%), five patients with complex hyperplasia without atypia (4.9%), and two patients with complex hyperplasia with atypia (1.9%). Histopathological evaluation of endometrial tissue obtained from hysterectomy specimens (of patients diagnosed with hyperplasia on curettage) revealed a total number of 65 cases (63.1%) with endometrial hyperplasia, and 38 cases (36.9%) with various histopathological findings. The correlation between preoperative and postoperative endometrial histologic findings was found to be statistically insignificant (r = 0.105, p = 0.29). Among 94 patients who were found to have simple hyperplasia without atypia on curettage specimens, 55.3%, were found to have simple hyperplasia without atypia, 1.1% simple hyperplasia with atypia, 5.3% complex hyperplasia without atypia, 9.6% secretory endometrium, 4.3% proliferative endometrium, 21.3% disorganized proliferative endometrium, 1.1% corpus luteum persistency, 1.1% basal endometrium, and 1.1% endometrium cancer on final hysterectomy specimens.

Conclusion: Postoperative diagnosis of endometrial pathology might be different from that of preoperative especially in cases with simple endometrial hyperplasia without atypia.

Endometrial hyperplasia; Histopathology; Atypia

[I] Ferenczy A., Gelfand M.: "The biologic significance of cytologic atypia in progestin-treated endometrial hyperplasia". Am. J. Obstet. Gynecol., 1989, 160, 126.

[2] Gal D.: " Hormonal therapy for lesions of the endometrium" Semin. Oncol., 1986, 13, 33.

[3] Gordon M.D., Ireland K.: "Pathology of hyperplasia and carcinoma of the endometrium". Semin. Oncol., 1994, 21, 64.

[4] Randall T.C., Kurman R.J.: "Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40". Obstet. Gynecol., 1997, 90, 434.

[5] Guven M., Dikmen Y., Terek M.C., Ozsaran A.A., Itil l.M., Erhan Y.: "Metabolic effects associated with high-dose contiguous megestrol acetate administration in the treatment of endometrial pathology". Arch. Gynecol. Obstet., 2001, 265, 183.

[6] Vakiani M., Vavilis D., Agorastos T., Stamatoppoulos P., Assimaki A., Bontis J.: " Histopathological findings of the endometrium in patients with dysfunctional uterine bleeding". Clin. Exp. Obstet. Gynecol., 1996, 23, 236.

[7] Zarbo G., Caruso G., Zammitti M., Caruso S., Zarbo R.: "The effect of tamoxifen therapy on the endometrium". Eur. J. Gynecol Oncol., 2000, 21, 86.

[8] Kazandi M., Sendag F., Akercan F., Terek M.C., Ozsaran A., Dikmen Y.: "Ovarian cysts in postmenopausal tamoxifen-treated breast cancer patients with endometrial thickening detected by transvaginal sonography". Eur. J. Gynaecol. Oncol., 2002, 23, 257.

[9] Kurman R.J., Kaminski P.F., Norris H.J.: "The behaviour of endometrial hyperplasia: a long-term study of'untreated' hyperplasia in 170 patients". Cancer, 1985, 56, 403.

[10] Terakawa N., Kigawa J., Taketani Y., Yoshikawa H., Yajima A., Noda K. et al.: "The behavior of endometrial hyperplasia : a prospective study. Endometrial Hyperplasia Study Group". J. Obstet Gynecol. Res., 1997, 23, 223.

[11] Janicek M.F., Rosenshein N.B.: "Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia". Gynecol Oncol., 1994, 52, 373.

[12] Widra E.A., Dunton CJ., McHugh M., Palazzo J.: "Endometrial hyperplasia and the risk of carcinoma". Int. J. Gynecol. Cancer, 1995, 5, 233.

[13] Dunton C.J., Baak J.P., Palazzo J.P., van Diest P.J., McHugh M., Widra E.A.: "Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer". Am. J. Obstet. Gynecol., 1996, 174, 1518.

[14] Ohkawara S., Jobo T., Sato R., Kuramoto H.: " Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia". Eur. J. Gynaecol. Oncol., 2000, 21, 573.

[15] Kaku T., Tsukamoto N., Hachisuga T., Tsuruchi N., Sakai K., Hirakawa T. et al.: "Endometrial carcinoma associated with hyperplasia". Gynecol. Oncol., 1996, 60, 22.

[16] Silverberg S.G.: "Problems in the differential diagnosis of endometrial hyperplasia and carcinoma". Mod. Pathol., 2000, 13, 309.

[17] Langer R.D., Pierce J.J., O'Hanlan K.A., Johson S.R., Espeland M.A., Trabal J.F. et al.: "Transvaginal ultrasonography compared with endometrial biopsy for detection of endometrial disease. Postmenopausal estrogen/progestin interventions trial". N. Engl. J. Med., 1997, 18,337, 1792.

[18] Cohen I., Azaria R., Bernheim J., Tepper R., Sharony R., Beyth Y.: " Comparison of endometrial pathologies collected by hysterescopy and hysterectomy in postmenopausal breast cancer tamoxifen-treated patients". Eur. J. Gynecol. Oncol., 2000, 21, 418.

[19] Pehlivanov B., Malinova M., Grozdanov G.: "Progesterone challenge test for evaluation of endometrial hyperplasia in postmenopausal women". Folia Med., 1998, 40, 22.

[20] el-Maraghy M.A., el-Badawy N., Wafa G.A., Bishai N.: "Progesterone challenge test in postmenopausal women at high risk" Maturilas, 1994, 19, 53.

[21] Triwitayakorn A., Rojanasakul A.: "Management of endometrial hyperplasia: a retrospective analysis". J. Med. Assoc. Thai, 1999, 82, 33.

[22] Goker E.N., Sendag F., Tavmergen E., Levi R., Zekioglu O.: "Successful pregnancy in an infertile woman with endometrial hyperplasia and embryo transfer. A case report'". J. Reprod. Med., 2001, 46, 859.

[23] Kowalczyk C.L., Malone J., Peterson E.P., Jaques S.M., Leach R.E.: "Well-differentiated endometrial adenocarcinoma in an infertility patient with later conception. A case report". J. Reprod. Med., 1999, 44, 57.

[24] Perez-Medina T., Bajo J., Folgueira G., Haya J., Ortega P.: "Atypical endometrial hyperplasia treatment with progesterones and gonadotropin-releasing hormone analogues: Long term followup". Gynecol. Oncol., 1999, 73, 299.

[25] Grimbizis G., Tsalikis T., Tzioufa V., Kasapis M., Mantalenakis S.: "Regression of endometrial hyperplasia after treatment with the gonadotropin-releasing hormone analogue triptorelin: a prospective study". Hum. Reprod., 1999, 14, 479.

[26] Xie X., Lu W.G., Ye D.F., Chen H.Z., Fu Y.F.: "The value of curettage in diagnosis of endometrial hyperplasia". Gynecol. Oncol., 2002, 84, 135.

[27] Dietel M.: "The histopathological diagnosis of endometrial hyperplasia. Is there a need to simplify?". Virchow Arch., 2001, 439, 604.

[28] Mutter G.L., The Endometrium Collaborative Group: "Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos?" Gynecol. Oncol., 2000, 76, 287.

[29] Bergeron C., Nogales F., Masseroli M., Abeler V., Duvillard P., Muller-Holzner E. et al.: "A multicentric European study testing the reproducibility of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens". Am. J. Surg. Pathol., 1999, 23,1102.